Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alpha Tau Medical Ltd (DRTS) has announced a pivotal clinical study titled A Pivotal, Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of Intratumoral Alpha DaRT224 for the Treatment of Immunocompromised Patients With Cutaneous Squamous Cell Carcinoma. The study aims to evaluate the safety and efficacy of the Alpha DaRT224 treatment, focusing on the objective response rate (ORR) and secondary outcomes like progression-free survival (PFS) and overall survival (OS) over 12 months.
The intervention being tested is the Diffusing Alpha-Emitters Radiation Therapy (DaRT), delivered through DaRT seeds. This experimental treatment is designed to target malignant cutaneous squamous cell carcinoma in immunocompromised patients, offering a novel approach to cancer treatment.
The study design is interventional, featuring a single-group, open-label model without masking. The primary purpose is treatment, and the study will enroll up to 28 participants across multiple international centers.
Key dates for the study include a start date of September 22, 2024, with the last update submitted on September 3, 2025. These dates are crucial as they mark the timeline for recruitment and data collection, impacting the study’s progress and subsequent reporting.
The market implications of this study are significant for Alpha Tau Medical Ltd. Successful outcomes could enhance investor confidence and positively influence stock performance. The study’s progress will be closely watched by investors and competitors in the oncology sector, particularly those focusing on innovative cancer treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.